Core B: Biospecimen Core

项目摘要 胰管癌临床标本的控制性采集与处理 腺癌（PDAC）是转化研究中有效和全面计划的关键活动 在SPORE赠款的背景下。因此，生物样本核心（核心B）有一个首要目标：我们将 收集、储存、处理和分发来自该机构诊断为PDAC的患者的生物标本 为了促进基于生物标志物的转化研究：我们将从肿瘤中收集恶性细胞群 (from手术前和手术活组织检查）。我们还将收集正常胰腺癌前病变， 和PDAC患者的外周血。将采集血清和血浆用于相关研究和未来研究。 将在每例患者的整个病程（初始表现、治疗前、治疗后）中采集标本。 治疗/随访），并且在适当情况下，将检索来自先前活检/等的存档标本。 特别注意标本的获取（例如，快速处理组织以保存转录谱），以及 实行质量控制。将样本处理为细胞RNA、基因组DNA、全基因组 扩增的DNA和蛋白质提取物。我们还将收集纵向患者无细胞 用于下游分析的DNA样本。细胞群也将被有效冷冻或立即处理 用于患者来源的异种移植物和/或类器官产生。重要的是，我们将确保所有用于 研究广泛而准确地注释了临床（治疗前、治疗和随访）数据 和元数据，利用我们机构的生物信息学基础设施。专家病理学审查， 专门的GI病理学家将确保高质量的注释。本核心的目标将通过以下方式实现： 继续我们完善的癌症中心肿瘤库和之前的PDAC SPORE核心B的范围 成功和正在进行的，资助的努力，以收集固体胃肠道恶性肿瘤在我们的机构。 具体而言，核心B将扩大采集生物标本的PDAC患者数量， 作为一个渠道（通过数据和标本共享），以允许更广泛的各种转化研究 PDAC恶性肿瘤研究，使用新的和以前储存的生物标本。

PROJECT SUMMARY The controlled collection and processing of clinical specimens from patients with pancreatic ductal adenocarcinoma (PDAC) is a critical activity for an efficient and comprehensive program in translational research in the context of a SPORE grant. Accordingly, the Biospecimen Core (Core B) has one overarching aim: We will collect, store, process, and distribute biospecimens from patients with a diagnosis of PDAC seen at this institution to facilitate biospecimen-based translational research: We will collect malignant cell populations from tumors (from pre-surgical and surgical biopsies). We will also collect normal pancreas, pre-malignant pancreatic lesions, and peripheral blood from PDAC patients. Serum and plasma will be collected for correlative and future studies. Specimens will be collected throughout each patient's disease course (initial presentation, pre-treatment, post- treatment/follow-up), and, where appropriate, archival specimens from previous biopsies/etc. will be retrieved. Particular attention to specimen procurement (e.g. rapid processing of tissue to preserve transcript profiles) and quality control will be practiced. Specimens will be processed to cellular RNA, genomic DNA, whole genome amplified DNA, and protein extracts as required for each study. We will also collect longitudinal patient cell-free DNA samples for downstream analysis. Cellular populations will also be viably frozen or immediately processed for patient-derived xenograft and/or organoid creation. Importantly, we will ensure that all specimens used for research are extensively and accurately annotated with clinical (pre-treatment, treatment, and follow-up) data and metadata utilizing the bioinformatics infrastructure at our institution. Expert pathologic review from a dedicated GI pathologist will ensure high-quality annotation. The aims of this Core will be accomplished by continuing the scope of our well-established Cancer Center Tumor Bank and prior PDAC SPORE Core B successes and an on-going, funded effort to collect solid gastrointestinal malignancies at our institution. Specifically, Core B will expand the number of PDAC patients from whom biospecimens will be collected, and serve as a conduit (through data and specimen sharing) to allow for a broader variety of translational research studies in PDAC malignancies, using new and previously banked biospecimens.